ERBB2 and breast neoplasm: Interestingly, all but one of the HSD17B14 deletion carrier breast tumors with pathology data available were of Luminal A subtype (21/22, 95%, P = 0.04, OR = 6.52, 95% CI = 0.88–48.63), and all were negative for HER2 amplification (22/22, 100%, P = 0.06, Table E in S2 Text).